Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis

被引：3
作者：
Righini, Matteo [1 ,2 ]
Mollica, Veronica [3 ,4 ]
Rizzo, Alessandro [5 ]
La Manna, Gaetano [2 ]
Massari, Francesco [3 ,4 ]
机构：
[1] Santa Maria Croci Hosp, Nephrol & Dialysis Unit, AUSL Romagna, I-48121 Ravenna, Italy
[2] Univ Bologna, Dialysis & Transplantat Unit, Nephrol, IRCCS Azienda Osped Univ Bologna, I-40126 Bologna, Italy
[3] Univ Bologna, Med Oncol, IRCCS Azienda Osped, Via Albertoni 15, I-40138 Bologna, Italy
[4] Univ Bologna, Dept Expt Diagnost & Specialty Med, I-40126 Bologna, Italy
[5] Ist Ric Cura Carattere Sci IRCCS, Struttura Semplice Dipartimentale Oncol Med Presa, I-70124 Bari, Italy
来源：
JOURNAL OF CLINICAL MEDICINE | 2022年 / 11卷 / 15期
关键词：
immune-checkpoint inhibitors; meta-analysis; renal toxicity; PD-1; inhibitors; PD-L1; chronic kidney disease; acute kidney injury; ADVERSE EVENTS; NIVOLUMAB; CHEMOTHERAPY; PEMBROLIZUMAB; DOCETAXEL; RISK; IMMUNOTHERAPY; MULTICENTER; IPILIMUMAB; MELANOMA;
D O I：
10.3390/jcm11154373
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Aim: We performed a meta-analysis of the available clinical trials of immune-checkpoint inhibitors to assess risk differences and relative risks of renal toxicity. Methods: 17 randomized phase III studies were selected, including 10,252 patients. Results: The administration of immune-checkpoint inhibitors resulted in an overall low-grade, high-grade and all-grade renal toxicity Risk Difference of: 0.746% (95% CI 0.629% to 1.15%, p < 0.001-random), 0.61% (95% CI, 0.292-0.929%, p < 0.001-fixed) and 1.2% (95% CI, 0.601-1.85%-random), respectively. The pooled Relative Risk of low-grade, high-grade and all-grade renal toxicity was: 2.185 (95% CI 1.515-3.152-fixed), 2.610 (95% CI, 1.409-4.833, p = 0.002-fixed) and 2.473 (95% CI, 1.782-3.431, p < 0.001-fixed), respectively. An increased risk of renal toxicity was evident in some subgroups more than others. Conclusion: Immune-checkpoint inhibitors are associated with an increased risk of renal toxicity.
引用
收藏
页数：17
相关论文
共 50 条
  • [31] The efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer patients of different age groups: a meta-analysis
    Zheng, S. -Y.
    Cui, H. -J.
    Duan, H.
    Peng, Y. -M.
    Li, Q.
    Sun, C. -Y.
    Zhang, J. -Y.
    Shen, W.
    Zhang, X.
    Tan, K.
    Jiang, X.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (07) : 1146 - 1154
  • [32] Hepatitis B reactivation in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis
    Xia, Zhengzheng
    Zhang, Jianyu
    Chen, Wenjun
    Zhou, Haiyan
    Du, Di
    Zhu, Kongcai
    Chen, Hui
    Meng, Jun
    Yang, Jun
    INFECTIOUS DISEASES OF POVERTY, 2023, 12 (01)
  • [33] The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression
    Kim, C. M.
    Lee, J. B.
    Shin, S. J.
    Ahn, J. B.
    Lee, M.
    Kim, H. S.
    ESMO OPEN, 2022, 7 (05)
  • [34] Comparative Risk of Renal Adverse Events in Patients Receiving Immune Checkpoint Inhibitors: A Bayesian Network Meta-Analysis
    Liu, Kang
    Qin, Zhongke
    Xu, Xueqiang
    Li, Ting
    Ge, Yifei
    Mao, Huijuan
    Xing, Changying
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [35] Management of toxicities of immune checkpoint inhibitors
    Spain, Lavinia
    Diem, Stefan
    Larkin, James
    CANCER TREATMENT REVIEWS, 2016, 44 : 51 - 60
  • [36] Cardiac adverse events of immune checkpoint inhibitors in oncology patients: A systematic review and meta-analysis
    Nso, Nso
    Antwi-Amoabeng, Daniel
    Beutler, Bryce D.
    Ulanja, Mark B.
    Ghuman, Jasmine
    Hanfy, Ahmed
    Nimo-Boampong, Joyce
    Atanga, Sirri
    Doshi, Rajkumar
    Enoru, Sostanie
    Gullapalli, Nageshwara
    WORLD JOURNAL OF CARDIOLOGY, 2020, 12 (11): : 584 - 598
  • [37] Efficacy of immune checkpoint inhibitors for NSCLC in patients with different age: A systematic review and meta-analysis
    Zhang, Qi
    Liang, Xiao-yan
    Wang, Ze-sheng
    Sun, An
    Cao, Tin-bao
    Zhang, Yu-Peng
    Li, Nan
    Yi, Tong-ying
    Qu, Kun-Peng
    ASIAN JOURNAL OF SURGERY, 2024, 47 (11) : 4691 - 4698
  • [38] Adverse events associated with immune checkpoint inhibitors in patients with breast cancer: A systematic review and meta-analysis
    Balibegloo, Maryam
    Nejadghaderi, Seyed Aria
    Sadeghalvad, Mona
    Soleymanitabar, Alireza
    Nezamabadi, Sasan Salehi
    Saghazadeh, Amene
    Rezaei, Nima
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 96
  • [39] Predictors for clinical benefit of immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis
    El-Osta, Hazem
    Jafri, Syed
    IMMUNOTHERAPY, 2019, 11 (03) : 189 - 199
  • [40] Geographic heterogeneity in the outcomes of patients receiving immune checkpoint inhibitors for advanced solid tumors: a meta-analysis
    Li, Manyu
    Yao, Jiannan
    Zhang, Huiyun
    Ge, Yang
    An, Guangyu
    TRANSLATIONAL CANCER RESEARCH, 2021, 10 (01) : 310 - +
12345